| Literature DB >> 33420357 |
Stephen Y Chan1, Partha Dutta2,3, Jonathan Florentin4, Jingsi Zhao4, Yi-Yin Tai4, Sathish Babu Vasamsetti4, Scott P O'Neil4, Rahul Kumar5, Anagha Arunkumar4, Annie Watson4, John Sembrat4,6, Grant C Bullock4,7, Linda Sanders8, Biruk Kassa5, Mauricio Rojas4,6, Brian B Graham8.
Abstract
Myeloid cells, such as neutrophils, are produced in the bone marrow in high quantities and are important in the pathogenesis of vascular diseases such as pulmonary hypertension (PH). Although neutrophil recruitment into sites of inflammation has been well studied, the mechanisms of neutrophil egress from the bone marrow are not well understood. Using computational flow cytometry, we observed increased neutrophils in the lungs of patients and mice with PH. Moreover, we found elevated levels of IL-6 in the blood and lungs of patients and mice with PH. We observed that transgenic mice overexpressing Il-6 in the lungs displayed elevated neutrophil egress from the bone marrow and exaggerated neutrophil recruitment to the lungs, resulting in exacerbated pulmonary vascular remodeling, and dysfunctional hemodynamics. Mechanistically, we found that IL-6-induced neutrophil egress from the bone marrow was dependent on interferon regulatory factor 4 (IRF-4)-mediated CX3CR1 expression in neutrophils. Consequently, Cx3cr1 genetic deficiency in hematopoietic cells in Il-6-transgenic mice significantly reduced neutrophil egress from bone marrow and decreased neutrophil counts in the lungs, thus ameliorating pulmonary remodeling and hemodynamics. In summary, these findings define a novel mechanism of IL-6-induced neutrophil egress from the bone marrow and reveal a new therapeutic target to curtail neutrophil-mediated inflammation in pulmonary vascular disease.Entities:
Keywords: CX3CR1; IL-6; inflammation; neutrophil; pulmonary hypertension
Mesh:
Substances:
Year: 2021 PMID: 33420357 PMCID: PMC8027442 DOI: 10.1038/s41423-020-00608-1
Source DB: PubMed Journal: Cell Mol Immunol ISSN: 1672-7681 Impact factor: 11.530